The cfDNA Purification Kit (Magnetic Beads) was developed for cell free DNA (cfDNA) enrichment by separating genomic DNA contamination from isolated cfDNA samples.
Many diagnostic technologies for detection of disease signals in cfDNA begin with isolation and purification of DNA from liquid biopsy that include urine, plasma, cerebrospinal fluid. The most widely explored biotechnology is assays used to detect cancer-derived plasma cfDNA. Silica-based magnetic bead cfDNA isolation kits can reliably extract total DNA from plasma, but typically yield a large variation in cfDNA that includes the presence of genomic DNA that often depends on tumor stage, tumor size, or healthy status individuals. Most of the commercial cfDNA isolation kits can’t specifically recover the cfDNA while leaving the high molecular weight genomic DNA behind. The presence of genomic DNA can lead to decreased sensitivity or inconsistent results in downstream applications such as next-generation sequencing (NGS), PCR, QPCR, and digital PCR etc.
Therefore, an additional purification step to enrich cfDNA before downstream methods helps to improve signal from fragments that originate from cancer cells. A proportion of cancer-derived cfDNA fragment signals are below 100 bp and are often not detectable except by qPCR or single-stranded DNA based library preparation for NGS (1, 2, 3). Furthermore only 1% of cancer-derived fragments are found above 400 bp (1, 2). Capture of size-selected fragments between 90-150 bp improved detection of cancer by 2-4 fold (4). Furthermore, TF-bound and protected cfDNA fragments are also being investigated for active cancer-specific signals down to 35-80 bp (5, 6).
This kit uses Dual Solid Phase Reversible Immobilization (SPRI) technology for cfDNA purification. Most Dual SPRI procedures do NOT recover fragments below 100 bp. The kit can be used for the enrichment of cfDNA isolated from liquid biopsies, plasma, serum, and urine. The kit separates cfDNA (50-500 bp) and genomic DNA, and recovers of 90% of the cfDNA without the high molecular weight genomic DNA with high efficiency. Fragments at 500 bp and above may also be retained. Both the 50-500 bp and >500 bp DNA fractions can be used for downstream applications such as single-stranded or double stranded NGS library prep, qPCR, ddPCR, and other methods.
Features
Examples of cfDNA purification. Both cfDNA and genomic DNA can be recovered separately.
The range of recovered small DNA fragments is from 50 to 500 bp. The input DNA are mixtures of sheared small DNA fragments and intact genomic DNA. The ratios of sheared DNA fragments versus genomic DNA are indicated.
Recovery rates of cfDNA and genomic DNA.
Many diagnostic technologies for detection of disease signals in cfDNA begin with isolation and purification of DNA from liquid biopsy that include urine, plasma, cerebrospinal fluid. The most widely explored biotechnology is assays used to detect cancer-derived plasma cfDNA. Silica-based magnetic bead cfDNA isolation kits can reliably extract total DNA from plasma, but typically yield a large variation in cfDNA that includes the presence of genomic DNA that often depends on tumor stage, tumor size, or healthy status individuals. Most of the commercial cfDNA isolation kits can’t specifically recover the cfDNA while leaving the high molecular weight genomic DNA behind. The presence of genomic DNA can lead to decreased sensitivity or inconsistent results in downstream applications such as next-generation sequencing (NGS), PCR, QPCR, and digital PCR etc.
Mycobacterium tuberculosis is a pathogenic bacterial species belonging to the genus Mycobacterium, and is the causative agent of tuberculosis. Tuberculosis (TB) is a multifaceted disease and challenging public health problem in both industrialized and developing countries. According to the WHO, 8.8 million active cases of TB are diagnosed each year and of these, almost 2 million die. Once thought to be under control or even close to extinction, TB infection levels are rising and the threat is compounded by new, virulent and drug-resistant strains. Although most cases occur in the developing world (22 countries accounting for 80% of all global cases), increasing population mobility combined with facility of transmission means that no country is immune from the resurgence of TB. TB control programs are currently facing a number of constraints. Worldwide, fewer than 25% of all tuberculosis cases are detected. Of utmost concern is the absence of a timely and accurate test for the diagnosis of mycobacterial disease. Early diagnosis is crucial for the prevention of further spread of the disease.
Mycobacterium tuberculosis TaqMan PCR Kit, 100 reactions
Mycobacterium tuberculosis TaqMan PCR Probe/Primer Set and Controls, 100 reactions
Figure 1 / 3
Click for expanded view
Storage Conditions and Product Stability
All kit components can be stored for 2 years after the date of production without showing any reduction in performance.
All kit components should be stored at -20°C upon arrival.
| Component | Cat. TM42150 (100 preps) | Cat. TM42110 (100 preps) |
|---|---|---|
| MDx TaqMan 2X PCR Master Mix | 2 x 700 μL | – |
| M. tuberculosis Primer & Probe Mix | 280 μL | 280 μL |
| M. tuberculosis Positive Control | 150 μL | 150 μL |
| Nuclease-Free Water (Negative Control) | 1.25 mL | 1.25 mL |
| Product Insert | 1 | 1 |
Name of Product
IL-6 / Interleukin-6 Test
Catalog Number
MQL6 1
Short Info
Test for the semi-quantitative evaluation of human Interleukin-6 (IL-6) in serum, plasma, cell culture supernatant, amnitotic fluid or cerebrospinal fluid.
This product is only available within the EU!
Method/Platform
lateral flow
Range/Assay Sensivity
50 to 10 000 pg/ml
Test Principle
IL-6 binds to a first anti IL-6 antibody conjugated to gold particles. The IL-6 loaded gold particles diffuse through the membrane and overflow the test line.
A second monoclonal antibody, specific for IL-6 is coated on the membrane. The gold particles are bound specifically and become visible as a coloured line. Colour intensity is directly proportional to the concentration of IL-6 in the sample. The conjugated specific antibodies printed as a second line on the membrane captures the rest of gold conjugate.
20 tests
Test for the semi-quantitative evaluation of human Interleukin-6 (IL-6) in serum, plasma, cell culture supernatant, amnitotic fluid or cerebrospinal fluid.